Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents

Journal of Bone and Joint Surgery

Volumn 89, Issue 8, 2007, Pages 1727-1734

  Ramachandran, Manoj ^a   Ward, Kate ^a   Brown, Richard R ^b   Munns, Craig F ^a   Cowell, Christopher T ^a   Little, David G ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; MEDRONATE TECHNETIUM TC 99M; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADOLESCENT; ARTICLE; BONE NECROSIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; EPIPHYSIS; FEMALE; FEMUR HEAD NECROSIS; FEMUR NECK FRACTURE; FOLLOW UP; GLOBAL PEDIATRIC OUTCOMES DATA COLLECTION INSTRUMENT; HARRIS HIP SCORE; HIGH RISK POPULATION; HIP DISLOCATION; HIP INJURY; HIP SURGERY; HUMAN; IOWA HIP RATING SCALE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION;

EID: 34547745839     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.F.00964     Document Type: Article

References (45)

1. Loder RT, Richards BS, Shapiro PS, Reznick LR, Aronson DD. Acute slipped capital femoral epiphysis: the importance of physeal stability. J Bone Joint Surg Am. 1993;75:1134-40.
2. Peterson MD, Weiner DS, Green NE, Terry CL. Acute slipped capital femoral epiphysis: the value and safety of urgent manipulative reduction. J Pediatr Orthop. 1997;17:648-54.
3. Carney BT, Weinstein SL, Noble J. Long-term follow-up of slipped capital femoral epiphysis. J Bone Joint Surg Am. 1991;73:667-74.
4. Morsy HA. Complications of fracture of the neck of the femur in children. A long-term follow-up study. Injury. 2001;32:45-51.
5. Forlin E, Guille JT, Kumar SJ, Rhee KJ. Complications associated with fracture of the neck of the femur in children. J Pediatr Orthop. 1992;12:503-9.
6. Hamilton PR, Broughton NS. Traumatic hip dislocation in childhood. J Pediatr Orthop. 1998;18:691-4.
7. Mehlman CT, Hubbard GW, Crawford AH, Roy DR, Wall EJ. Traumatic hip dislocation in children. Long-term followup of 42 patients. Clin Orthop Relat Res. 2000;376:68-79.
8. Kim HK, Su PH. Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model. J Bone Joint Surg Am. 2002;84:1329-34.
9. Pringle D, Koob TJ, Kim HK. Indentation properties of growing femoral head following ischemic necrosis. J Orthop Res. 2004;22:122-30.
10. Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord. 2002;3:19.
11. Little DG, Peat RA, McEvoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003;18:2016-22.
12. Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am. 2005;87:550-7.
13. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005;44:352-9. Erratum in: Rheumatology (Oxford). 2005;44:569.
14. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87:2155-9.
15. Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res. 2006;443:273-9.
16. Rhoad RC, Davidson RS, Heyman S, Dormans JP, Drummond DS. Pretreatment bone scan in SCFE: a predictor of ischemia and avascular necrosis. J Pediatr Orthop. 1999;19:164-8.
17. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737-55.
18. Larson CB. Rating scale for hip disabilities. Clin Orthop Relat Res. 1963; 31:85-93.
19. Pencharz J, Young NL, Owen JL, Wright JG. Comparison of three outcomes instruments in children. J Pediatr Orthop. 2001;21:425-32.
20. Stulberg SD, Cooperman DR, Wallensten R. The natural history of Legg-Calve-Perthes disease. J Bone Joint Surg Am. 1981;63:1095-108.
21. Neyt JG, Weinstein SL, Spratt KF, Dolan L, Morcuende J, Dietz FR, Guyton G, Hart R, Kraut MS, Lervick G, Pardubsky P, Saterbak A. Stulberg classification system for evaluation of Legg-Calvé-Perthes disease: intra-rater and inter-rater reliability. J Bone Joint Surg Am. 1999;81:1209-16.
22. Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br. 1985;67:3-9.
23. Hogler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701-4.
24. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. CDC growth charts: United States. Adv Data. 2000;314:1-27.
25. Boyer DW, Mickelson MR, Ponseti IV. Slipped capital femoral epiphysis. Long-term follow-up study of one hundred and twenty-one patients. J Bone Joint Surg Am. 1981;63:85-95.
26. Ross PM, Lyne ED, Morawa LG. Slipped capital femoral epiphysis long-term results after 10-38 years. Clin Orthop Relat Res. 1979;141:176-80.
27. Krahn TH, Canale ST, Beaty JH, Warner WC, Lourenco P. Long-term follow-up of patients with avascular necrosis after treatment of slipped capital femoral epiphysis. J Pediatr Orthop. 1993;13:154-8.
28. Mullins MM, Sood M, Hashemi-Nejad A, Catterall A. The management of avascular necrosis after slipped capital femoral epiphysis. J Bone Joint Surg Br. 2005;87:1669-74.
29. Gent E, Clarke NM. Joint replacement for sequelae of childhood hip disorders. J Pediatr Orthop. 2004;24:235-40.
30. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87:1609-18.
31. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-52.
32. Ciana G, Cuttini M, Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med. 1997; 337:712.
33. Little DG, Cornell MS, Briody J, Cowell CT, Arbuckle S, Cooke-Yarborough CM. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J Bone Joint Surg Br. 2001;83:1069-74.
34. Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, Gardiner EM, Cowell CT. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res. 2003;18:1300-7.
35. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res 2005;23:1029-34.
36. Aronsson DD, Loder RT. Treatment of the unstable (acute) slipped capital femoral epiphysis. Clin Orthop Relat Res. 1996;322:99-110.
37. Tokmakova KP, Stanton RP, Mason DE. Factors influencing the development of osteonecrosis in patients treated for slipped capital femoral epiphysis. J Bone Joint Surg Am. 2003;85:798-801.
38. Fragniere B, Chotel F, Vargas Barreto B, Berard J. The value of early post-operative bone scan in slipped capital femoral epiphysis. J Pediatr Orthop B. 2001;10:51-5.
39. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
40. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
41. Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone. 2003;32:268-74.
42. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111:1030-6.
43. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997;76:266-83.
44. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000;85:3109-15.
45. Kim HK, Sanders M, Athavale S, Bian H, Bauss F. Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone. 2006;39:205-12.